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More than 1600 different sequence variations have been reported in the CFTR gene
and the mutational spectrum varies in accordance with geographic and/or ethnic
origins of patients.
According to the recommendations from best practice guidelines, it is advisable to
offer to patients/relatives/partners a mutation detection rate higher than 80% includ-
ing population-speciﬁc mutations with relative frequencies above 1%. Additional
mutation screening using scanning methods (DGGE, DHPLC, HRM) or sequencing
should be performed to complete the search of the most frequent mutations by
commercial kits, however they permitted the identiﬁcation of rare/unclassiﬁed
variants. As the results of a genetic test can have serious implications for an
individual and his family, it is important to identify, particularly in carrier screening
or in case of suspicion of CF in fetuses with bowel hyperechogenic, only CF-causing
mutations.
We designed 3 population-speciﬁc (North African, Spanish and Italian) home-made
kits based on SNaPshot method (single nucleotide primer extension with dideoxy
nucleotide, migration on 3130 Genetic Analyser and interpretation of results using
GeneMapper Software from Applied Biosystem). According to literature data, each
panel includes mutation subsets (6 to 9 different disease-causing mutations) shown
to be frequent in French subjects with foreign origins and allows the identiﬁcation
of both wild type and mutant alleles.
In order to avoid misinterpretation of unclassiﬁed missenses or putative splice
mutations, only variants of proven or certain clinical relevance are included in these
panels. This accurate, speciﬁc, sensible and rapid method can easily be adapted and
developed to other population-speciﬁc mutations.
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NBS for CF was implemented throughout France in 2002 using a four-tiered
strategy: IRT1/DNA analysis (CF30 Elucigene Kit)/IRT2/ST.
Then, complete scanning and search for large rearrangements were performed in
infants presenting positive or borderline sweat tests in which both mutations had
not been identiﬁed by the kit. All data were collected by the French Association
for NBS (AFDPHE).
987 CF neonates were diagnosed. The CF30 kit offered an excellent detection
mutation rate: 86% (over 80% for all of France except for two regions); at least
one mutant allele was identiﬁed in 98% and two in 75%.
273 alleles were subjected to exhaustive genotyping analysis, enabling identiﬁcation
of 99.3% of mutant alleles. French allelic heterogeneity was conﬁrmed: 190 different
mutations, 260 different genotypes.
The spectrum of CFTR mutations was signiﬁcantly different from that reported
in CF patients diagnosed on clinical symptoms (Claustres, 2000): lower F508del
percentage (62.6%), higher rates of mutation associated with milder phenotypes
(R117H; 7T: 4.4%, L206W: 0.8%, R347H: 0.5%), and unclassiﬁed rare variants.
TIR/DNA strategy enabling very early diagnosis of classical forms of CF was
successful. However, we detected up to 14% of neonates with mild or rare
unclassiﬁed variants whose individual outcome cannot be accurately predicted.
Collaborative studies (clinical, epidemiological and functional) to better assess the
pathogenicity of these variants are underway and will be discussed.
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Nonsense mutations are usually linked with severe disease; however atypical mild
pulmonary illness with severe pancreatic insufﬁciency has already been described
in CF patients with two nonsense mutations. Very mild CF was diagnosed in two
siblings homozygous for the mutation E831X, located at the ﬁrst nucleotide of
exon 14a. Now aged of 29 y (woman) and 13 y (boy), they are pancreatic sufﬁcient,
have very mild pulmonary manifestations but have positive sweat tests. Screening
of the 27 exons failed to identify another mutation.
RT-PCR performed on mRNA obtained from nasal brushing has shown the presence
of one full-length and one exon 14a deleted mRNA isoforms as conﬁrmed by direct
sequencing. The ﬁrst isoform would lead to a half-CFTR (after the R domain) and
the second one would result in an in-frame exon 14a skipping. This latter form
is predicted to produce a short deletion (from aa 831 to 872) of a cytoplasmic
portion between the R domain and the seventh transmembrane segment. Two stable
cell lines expressing each mutated protein have been established and biochemical
analysis performed. Immunoblot revealed a truncated protein at the expected size for
E831X-CFTR while CFTR del(831–873) generated a core-glycosylated protein. We
have performed a blue native (BN)/SDS-PAGE showing a lower mobility (i.e. high
molecular weight) of the truncated protein suggesting its possible multimerization.
This could account for the very mild phenotype observed, however functional
studies of both CFTR isoforms are ongoing to further characterize this mutant.
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In the ATP binding cassette (ABC) transporters superfamily, MRP (Multidrug
Resistance Protein)-1 shares the closest homology with CFTR, which is defective
in CF disease. Functional replacement of CFTR by MRP1 has been previously
suggested. We investigated the possible association of MRP1 promoter 5′FR/G-
260C polymorphism with severity of CF disease. 130 non-CF subjects and 234
CF patients homozygous for F508del mutation were genotyped by snapshot: no
signiﬁcantly different allelic frequencies between groups were found. Association
of polymorphism with disease severity as assessed by FEV1, BMI, diabetes and
Pseudomonas aeruginosa chronic infection was not statistically signiﬁcant. The
CC genotype tended to be linked to higher rate of chronic colonization by PA
as well as with earlier chronic colonization by PA but these trends did not reach
statistical signiﬁcance. Allelic frequencies in 20 CF patients were not in relation
with MRP1 mRNA levels and basal/cAMP-stimulated anion conductance in nasal
epithelial cells. Gene reporter assays were performed in two CF and one isogenic
non-CF airway cell lines: no relevance of the 5′FR/G-260C variant was found for
the MRP1 promoter transcriptional activity.
Our results did not show any statistically signiﬁcant impact of MRP1(5′FR/G-260C)
polymorphism on disease severity and MRP1 transcription.
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